Question explored with the scientific record
Conversation so far
- 1 what is the solution for a 74 year old man, healthy otherwise with long covid + a private exchange
- 2 What treatments have evidence specifically for people age 70+? + a private exchange
- 3 The only randomized trial of creatine for post-viral fatigue enrolled adults 18 to 65, gave 4 grams daily for six months, and found improvements in fatigue, breathing difficulty, body aches, headache, and concentration, with one case of mild nausea 6 GIVE ME A LINK TO THE ACTUAL SUCCESSFUL STUDY
Answered on this page ↓
The only randomized trial of creatine for post-viral fatigue enrolled adults 18 to 65, gave 4 grams daily for six months, and found improvements in fatigue, breathing difficulty, body aches, headache, and concentration, with one case of mild nausea 6 GIVE ME A LINK TO THE ACTUAL SUCCESSFUL STUDY
The short version: the trial you are asking about exists in this retrieval, but it is a small pilot, not a definitive study.
The randomized, double-blind, placebo-controlled trial enrolled 12 adults aged 18 to 65 with post-viral fatigue after COVID-19 [1]. It gave 4 grams of creatine monohydrate daily for six months [1]. It found improvements in general fatigue, ageusia, breathing difficulty, body aches, headache, and concentration, plus better exercise tolerance on walking tests [1]. One case of mild, transient nausea was reported [1]. Tissue creatine rose in muscle and brain at 3 and 6 months [1].
That is the whole evidence base. Twelve people. No funding source is disclosed in the retrieval. No replication study appears here. The trial is mechanistically plausible, since creatine supports mitochondrial energy production and long COVID involves mitochondrial dysfunction [1, 3]. But a single 12-person pilot is a signal, not proof. The burden of proof for an intervention on a sick body is not met by one small trial.
My call: creatine 4 g daily for six months is a reasonable, low-risk option for post-viral fatigue, but the evidence is a single small pilot with no replication. Confidence: low.
Sources examined 6
-
Creatine as a mitochondrial theranostic in predictive, preventive, and personalized medicine
This mini-review advocates creatine as a mitochondria-targeted theranostic within predictive, preventive, and personalized medicine (PPPM), synthesizing mechanistic evidence of mitochondrial support with clinical data showing diagnostic potential and therapeutic benefits in cond…
DOI: 10.1007/s13167-025-00420-9 -
The effects of single-dose colloidal creatine (creaphil™) vs. creatine monohydrate on biomarkers of skeletal muscle bioenergetics in healthy men
This study investigates the effects of a novel colloidal creatine formulation (Creaphil™) compared to creatine monohydrate on biomarkers of skeletal muscle bioenergetics in healthy men, finding that Creaphil™ significantly enhances creatine levels in muscle and plasma without ad…
DOI: 10.1016/j.clnu.2018.06.1599 -
Creatine as a Compound and Supplement Metabolism, Mechanism of Action, Effects, and Adverse Effects - A Review
A comprehensive narrative review synthesizing creatine's metabolism, mechanism of action, athletic and non-athletic effects, dosing strategies, safety, and potential adverse effects across diverse populations.
DOI: 10.12775/qs.2025.41.60164 -
Creatine supplementation and health variables: a retrospective study
A retrospective study of 26 athletes examined long-term creatine monohydrate supplementation (up to 4 years) for health markers, side effects, and perceived ergogenic benefits, finding no adverse health effects and generally positive perceived benefits.
DOI: 10.1097/00005768-200102000-00002 -
Co-Administration of Creatine and Vitamin D and Telomere Length in Older Men: An Exploratory Pilot Trial
Daily creatine monohydrate plus vitamin D3 for 12 months in healthy men aged 65+ was associated with longer leukocyte telomeres (~11% higher) than age-matched controls in an open-label pilot with good adherence and no adverse effects.
DOI: 10.37290/ctnr.v24i1.28 -
Reduction of myocardial ischemic injury following coronary intervention (The MC-1 to eliminate necrosis and damage trial)
This phase II pilot study demonstrates that treatment with pyridoxal-5-phosphate monohydrate (MC-1) significantly reduces myocardial ischemic injury, as indicated by a decrease in creatine kinase MB (CK-MB) levels, in high-risk patients undergoing elective percutaneous coronary …
DOI: 10.1016/s0002-9149(03)00818-x